Does a 3-day malaria combination pill work well in pregnancy?
In pregnant women on the Thai-Burmese border, the standard 3-day artemether-lumefantrine course was safe but cured fewer malaria infections than 7 days of artesunate, probably because pregnancy lowers drug levels.
Source
A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy
Study at a glance
- Design
- RCT — Open-label randomised trial with concealed allocation: 3-day artemether-lumefantrine vs 7-day artesunate, all doses directly observed; follow-up to delivery or day 42 and infants to 1 year
- N
- N=253 · 253 episodes of falciparum malaria in 252 pregnant women (125 artemether-lumefantrine, 128 artesunate; one woman randomised twice); day 7 lumefantrine levels measured in 85
- Population
- Karen and Burmese pregnant women in the second or third trimester with uncomplicated P. falciparum malaria attending antenatal clinics on the Thai-Burmese border
- Outcome
- Primary: PCR-adjusted parasitological cure at delivery or day 42 (whichever later); secondary: fever/parasite clearance, anaemia, adverse events, birth outcomes, infant growth and development to 1 year
Structured fields used in claim comparison tables when every cited study has a complete layer.
What they did
Pregnant women in their second or third trimester with uncomplicated falciparum malaria were randomly assigned, via sealed envelopes, to the standard six-dose, 3-day artemether-lumefantrine course or to artesunate once daily for 7 days, with every dose supervised in hospital. Women were checked weekly until delivery (or day 42 if later), and PCR genotyping distinguished true treatment failures (recrudescence) from new infections. Babies were examined at birth and followed for growth and development to 1 year, and day 7 blood lumefantrine levels were measured in a subgroup.
What they found
Artesunate cured more infections than artemether-lumefantrine; after censoring women who got P. vivax, cure rates were 92.2% versus 83.8% (p = 0.045), and both regimens fell below the WHO 90% benchmark in the main analysis. The gap came mainly from women entering with a recrudescent infection, while cure rates for new or first infections were similar. Nearly a third of recrudescences appeared after day 42, and every woman with day 7 lumefantrine above 600 ng/ml was cured versus 22% failure below that. Both drugs were well tolerated, with no differences in birth weight, gestation, congenital abnormalities or infant development.
The limits
What it doesn't show
Treatment was open-label because the regimens looked so different, although lab staff reading slides and PCR were blinded. The subgroup result on recrudescent infections was an exploratory analysis the trial was not designed for, and early recruitment was restricted to recurrent infections by an ethics committee. It was set in a low-transmission, multidrug-resistant area, so the authors caution that AL may work better where women have more immunity. The trial was not powered to detect differences in birth outcomes, and the higher infant death rate in the artesunate group was judged unrelated to treatment.
Key terms
- Artemisinin combination therapy (ACT)
- A malaria treatment pairing a fast-acting artemisinin derivative with a longer-acting partner drug, such as artemether with lumefantrine.
- Recrudescence
- Return of the same parasite infection after treatment because the drug failed to clear it, as opposed to a new infection.
- PCR-adjusted cure rate
- A cure rate in which genotyping is used to count only recrudescences as treatment failures and not new infections.
- Pharmacokinetics
- How the body absorbs, distributes and clears a drug; pregnancy lowers blood levels of several antimalarials.
- Kaplan-Meier survival analysis
- A method that estimates the proportion remaining event-free over time while handling people who leave follow-up early.
Flashcards
0 of 12 answers reviewed
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
What was the main efficacy finding of this trial?
Common questions
Why compare a combination drug against a single drug (monotherapy)?
At the time the protocol was written, 7-day artesunate was the local first-line treatment in later pregnancy, so it was the appropriate standard comparator.
Why do pregnant women respond worse than non-pregnant adults?
Pregnancy lowers blood concentrations of artemether and lumefantrine, parasites hide in the placenta, and immunity is reduced, so resistant parasites are more likely to survive.
What does this mean for how malaria drug trials in pregnancy should be run?
Follow-up should extend at least to delivery, because many treatment failures appeared after the usual 42-day window.
Did the higher cure rate with artesunate improve babies' outcomes?
No difference in birth outcomes was seen, but the trial was not powered to detect one.
More on Maternal health